Towards Healthcare
Artificial Lung Market Size Soars USD 2.78 Billion in 2025 at 10.84% CAGR

Artificial Lung Market Growth Accelerates in 2025 with North America Leading at 45% Share

According to market projections, the global artificial lung market, valued at USD 2.51 billion in 2024, is anticipated to reach USD 7.05 billion by 2034, growing at a CAGR of 10.84% over the next decade. The artificial lung market is growing due to rising respiratory disorders, especially COPD cases, which are the leading cause of death across the globe. North America dominated the market due to the region’s provision of advanced healthcare.

Content

  • Insight Code: 5830
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The artificial lung market is projected to reach USD 7.05 billion by 2034, growing at a CAGR of 10.84% from 2024 to 2034.

North America is currently leading the artificial lung market due to technological advancements, key players collaborations, and FDA approvals.

The artificial lung market includes six segments such as by product type, by application, by technology, by patient type, and by region.

Some key players include Medtronic plc, Getinge AB, Abbott Laboratories (Thoratec/HeartMate for hybrid devices), Xenios AG (a Fresenius Medical Care company), ALung Technologies, Inc., MicroPort Scientific Corporation, Abiomed (a Johnson & Johnson company), etc.

Key trends include rising research in developing better artificial lungs for long-term use, growing cases of COPD, and government initiatives.

An artificial lung can only temporarily replace lung function, even if artificial kidney or heart replacement has been a viable therapeutic alternative for a number of years.

The artificial lungs now in use are membrane blood oxygenators, which are made of silicone sheets in one design or microporous polypropylene hollow fiber membranes in another.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions